Honored and grateful to be among the 2026 Conquer Cancer Grants & Awards recipients. Thank you, @ConquerCancerFd and @ASCO for investing in the next generation of oncology researchers and leaders. Looking forward to #ASCO26 in Chicago! 🎗️🌍 #ResearchConquersCancer #ConquerCancer #ASCO26 #CancerResearch #Oncology #GlobalOncology #CancerCare #FutureOfOncology

🔬 Four important discussions from the final Presidential Sessions at #ESMO26! 💊 KEYNOTE-C93: Pembrolizumab monotherapy improved PFS in dMMR advanced or recurrent endometrial cancer, although the prespecified non-inferiority criterion was not met. An important step toward chemotherapy-free treatment. 🎯 Sacituzumab tirumotecan (sac-TMT): Impressive results in previously treated endometrial cancer, with improved PFS (7.2 vs 3.9 months) and OS (19.0 vs 12.1 months). ADCs are clearly changing the landscape! 🧬 MOIO trial: Can we safely extend immunotherapy intervals to every 3 months? The trial stopped early, leaving the question statistically unresolved and highlighting the challenges of treatment de-escalation. 📊 Non-inferiority: Who decides how much efficacy we can afford to lose? A great reminder that statistical margins must also reflect clinical judgment and patient preferences. Four discussions that could shape how we design trials and treat patients in the coming years. 💚 @osutcuoglu @uyargalip @kbaskurtt @tubaugurdr @drOrhunakdogan @myESMO #ESMO26 #ESMO2026 #Oncology #Immunotherapy #EndometrialCancer #ADC #ClinicalTrials

Great to finally meet Dr. Sumanta Pal at #ESMO26💚 His contributions to GU oncology have been truly remarkable. So much to learn from his work! @montypal @kbaskurtt @myESMO

💚 So happy to be featured in ESMO’s #ESMOcommunity video at #ESMO26 🌍 💫 More than science, oncology is about people, friendships, and a shared passion for better cancer care. 🙏 Thank you, @myESMO, for including me in this amazing community! @FLordick28391 @YJanjigianMD @MartinReck2 @FAndreMD @osutcuoglu @uyargalip @kbaskurtt #ESMO2026 #Oncology #CancerResearch #MedicalOncology #CancerCare #GlobalOncology #YoungOncologists #Madrid2026

🎉 Proud to present our study at #ESMO2026 in Madrid! 🇪🇸 (3904P) 🦴 In our prospective two-center study of 190 patients, adding loratadine to naproxen showed numerically lower G-CSF-induced bone pain (27.9% vs 32.7%), without statistical significance. 🧠 Greater pain was associated with poorer quality of life, sleep, mood, and anxiety. 💡 Bone pain is more than pain. Supportive care matters! 🏆 Proud to contribute four posters to ESMO as a team! 🙏 Grateful to the International Cancer Foundation for the travel grant and to all our collaborators! @myESMO @OncoAlert @uyargalip @kbaskurtt @osutcuoglu @RyanNipp #InternationalCancerFoundation #OneGlobalOncologyCommunity #ESMO26 #ESMO

🎉 Our new study is now published in JCO Global Oncology! 💊🖐️ Topical Diclofenac for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Prospective Real-World Study 🔬 In this prospective, two-center real-world study of 151 patients receiving capecitabine-based therapy, we evaluated prophylactic topical diclofenac for the prevention of clinically significant hand-foot syndrome (HFS). 📊 Grade ≥2 HFS occurred in 16.9% (12/71) with topical diclofenac versus 13.8% (11/80) with active monitoring (OR 1.28; 95% CI, 0.52–3.10; P = .591). 💡 Our findings showed that prophylactic topical diclofenac did not reduce clinically significant HFS or delay its onset in routine clinical practice, adding prospective real-world evidence to this evolving area of supportive oncology. 🙏 Special thanks to our first author, Dr. Orhun Akdoğan(@drOrhunakdogan) and our mentor, Dr. Osman Sütcüoğlu(@osutcuoglu) for their leadership and guidance, and to our entire team(@uyargalip, @kbaskurtt, @yucelbirkadriye) for their valuable contributions. Grateful to be part of this collaboration! 📖 @JCOGO_ASCO | @ASCO 🔗 ascopubs.org/doi/pdf/10.1200… #JCOGlobalOncology #ASCO #Oncology #SupportiveCare #Capecitabine #HandFootSyndrome #RealWorldEvidence @KVanLoonMD @RyanNipp @thenasheffect @IshwariaMD @ASCOPres